Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$75.75 USD
+0.29 (0.38%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $75.77 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$75.75 USD
+0.29 (0.38%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $75.77 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
Here's Why Merit Medical (MMSI) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Merit Medical (MMSI) Launches FDA-Cleared Micro-Access System
by Zacks Equity Research
Merit Medical (MMSI) announces the launch of its latest FDA-approved Micro ACE Advanced Micro-Access System, which is likely to benefit interventional treatments using micro access.
Why Merit Medical (MMSI) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
Merit Medical (MMSI) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the fourth quarter.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Compared to Estimates, Merit Medical (MMSI) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Merit Medical (MMSI) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Merit Medical (MMSI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 5.19% and 1.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cooper Companies (COO) in Q1 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal first-quarter results are likely to reflect segmental strength.
What's in Store for Patterson Companies (PDCO) in Q3 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments.
What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) fourth-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.
Stay Ahead of the Game With Merit Medical (MMSI) Q4 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Merit Medical (MMSI), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
The Cooper Companies (COO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
The Cooper Companies (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merit Medical (MMSI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Merit Medical (MMSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merit Medical's (MMSI) SCOUT Guidance System Gets FDA Nod
by Zacks Equity Research
Merit Medical's (MMSI) SCOUT MD Surgical Guidance System receives FDA clearance, which aims to boost the treatment of breast cancer by increasing accuracy to target tumor sites.
West Pharmaceutical Services (WST) Beats Q4 Earnings Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 2.81% and 0.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for West Pharmaceutical (WST) in Q4 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
What's in the Cards for Medtronic (MDT) in Q3 Earnings?
by Zacks Equity Research
Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal third-quarter performance.
Here's Why You Should Add HealthEquity (HQY) to Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Insulet (PODD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Insulet (PODD) is expected to have benefited from the ongoing rollout of Omnipod 5 in several international markets in the fourth quarter.
MMSI vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
MMSI vs. ALGN: Which Stock Is the Better Value Option?
Ecolab (ECL) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Ecolab's (ECL) fourth-quarter results are likely to be driven by its Food & Beverage, Water business along with the Institutional segment.
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the fourth quarter.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.